Daridorexant Hydrochloride Patent Expiration
Daridorexant Hydrochloride is Used for treating insomnia. It was first introduced by Idorsia Pharmaceuticals Ltd
Daridorexant Hydrochloride Patents
Given below is the list of patents protecting Daridorexant Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Quviviq | US10023560 | Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist | Dec 02, 2034 | Idorsia |
| Quviviq | US9790208 | Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist | Dec 02, 2034 | Idorsia |
| Quviviq | US9732075 | Benzimidazole-proline derivatives | Jun 12, 2033 | Idorsia |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Daridorexant Hydrochloride's patents.
Latest Legal Activities on Daridorexant Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Daridorexant Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail Pub Notice re 312 amendment | 31 May, 2024 | US9732075 |
| Email Notification Critical | 31 May, 2024 | US9732075 |
| POST ISSUE OTHER COMMUNICATION TO APPLICANT- CERTIFICATE OF CORRECTION | 28 May, 2024 | US9732075 |
| Second letter to regulating agency to determine regulatory review period | 23 Oct, 2023 | US9732075 |
| Letter from FDA or Dept of Agriculture re PTE application | 28 Sep, 2023 | US9732075 |
| Initial letter Re: PTE Application to regulating agency | 28 Dec, 2022 | US9732075 |
| Post Issue Communication - Certificate of Correction | 18 Nov, 2022 | US9732075 |
| Post Issue Communication - Certificate of Correction | 01 Aug, 2022 | US9732075 |
| Post Issue Communication - Certificate of Correction | 20 May, 2022 | US9732075 |
| Email Notification Critical | 29 Apr, 2022 | US9732075 |
Daridorexant Hydrochloride's Family Patents
